We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, Recursion Pharmaceuticals (RXRX - Free Report) closed at $4.03, marking a -4.95% move from the previous day. The stock's change was less than the S&P 500's daily loss of 1.82%. Elsewhere, the Dow saw a downswing of 1.09%, while the tech-heavy Nasdaq depreciated by 2.86%.
The biotechnology company's stock has climbed by 4.18% in the past month, falling short of the Medical sector's gain of 5.28% and outpacing the S&P 500's gain of 0.71%.
Analysts and investors alike will be keeping a close eye on the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company is predicted to post an EPS of -$0.24, indicating a 33.33% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $10.92 million, indicating a 110.83% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.93 per share and revenue of $42.82 million, indicating changes of +35.42% and -42.66%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Recursion Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.41% higher. Recursion Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 103, which puts it in the top 42% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
In the latest trading session, Recursion Pharmaceuticals (RXRX - Free Report) closed at $4.03, marking a -4.95% move from the previous day. The stock's change was less than the S&P 500's daily loss of 1.82%. Elsewhere, the Dow saw a downswing of 1.09%, while the tech-heavy Nasdaq depreciated by 2.86%.
The biotechnology company's stock has climbed by 4.18% in the past month, falling short of the Medical sector's gain of 5.28% and outpacing the S&P 500's gain of 0.71%.
Analysts and investors alike will be keeping a close eye on the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company is predicted to post an EPS of -$0.24, indicating a 33.33% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $10.92 million, indicating a 110.83% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.93 per share and revenue of $42.82 million, indicating changes of +35.42% and -42.66%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Recursion Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.41% higher. Recursion Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 103, which puts it in the top 42% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.